{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:57:39Z","timestamp":1783011459895,"version":"3.54.6"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1999,12,1]],"date-time":"1999-12-01T00:00:00Z","timestamp":944006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1999,12,1]],"date-time":"1999-12-01T00:00:00Z","timestamp":944006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[1999,12]]},"DOI":"10.1023\/a:1006343818656","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T01:36:27Z","timestamp":1040520987000},"page":"241-246","source":"Crossref","is-referenced-by-count":23,"title":["Peripheral Neuropathy Due to Biweekly Paclitaxel, Epirubicin and Cisplatin in Patients with Advanced Ovarian Cancer"],"prefix":"10.1007","volume":"45","author":[{"given":"T.J.","family":"Postma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hoekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.G.H.","family":"van Riel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Heimans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.B.","family":"Vermorken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"260710_CR1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0748-7983(96)92737-7","volume":"22","author":"JB Vermorken","year":"1996","unstructured":"Vermorken JB, Pecorelli S: Clinical trials in patients with epithelial ovarian cancer: past, present and future. Eur J Surg Oncol 22: 455\u2013466, 1996","journal-title":"Eur J Surg Oncol"},{"key":"260710_CR2","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1136\/bmj.303.6807.884","volume":"303","author":"Advanced Ovarian Cancer Trialists Group","year":"1991","unstructured":"Advanced Ovarian Cancer Trialists Group: Chemotherapy in advanced ovarian cancer: an overviewof randomised clinical trials. BMJ 303: 884\u2013893, 1991","journal-title":"BMJ"},{"key":"260710_CR3","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/0277-5379(91)90011-2","volume":"27","author":"JP Neijt","year":"1991","unstructured":"Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, van Oosterom AT, Willemse PHB, Vermorken JB, van Lindert ACM, Heintz APM, Aartsen E, van Lent M, Trimbos JB, de Meijer AJ: Long term survival in ovarian cancer. Mature data from The Netherlands joint study group for ovarian cancer. Eur J Cancer 27: 1367\u20131372, 1991","journal-title":"Eur J Cancer"},{"key":"260710_CR4","first-page":"361a","volume":"17","author":"M Markman","year":"1998","unstructured":"Markman M, Bundy B, Benda J, Alberts D, Wadler S, Fowler J, Clark-Pearson D, Carson LF: Randomized phase 3 study of intravenous cisplatin\/paclitaxel versus moderately high dose iv carboplatin followed by iv paclitaxel and intraperitoneal cisplatin in optimal residual ovarian cancer: an intergroup trial. Proc Am Soc Clin Oncol 17: 361a, 1998 (Abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"260710_CR5","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts DS, LiuPY, HanniganEW, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B, Adelson MD, Hoskins WJ: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.NEngl JMed 335: 1950\u20131955, 1996","journal-title":"NEngl JMed"},{"key":"260710_CR6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/0003-4819-111-4-273","volume":"111","author":"WP McGuire","year":"1989","unstructured":"McGuireWP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.Ann Intern Med111: 273\u2013279, 1989","journal-title":"Ann Intern Med"},{"key":"260710_CR7","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.1993.11.12.2405","volume":"11","author":"EL Trimble","year":"1993","unstructured":"Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, Christian MC, Canetta R, Onetto N, Hayn R, Arbuck SG: Paclitaxel for platinumrefractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 11: 2405\u20132410, 1993","journal-title":"J Clin Oncol"},{"key":"260710_CR8","first-page":"361a","volume":"17","author":"G Stuart","year":"1998","unstructured":"Stuart G, Bertelsen K, Mangioni C, Trope C, James K, Cassidy J, Kaye S, Timmers P, Roy JA, Piccart MJ: Updated analysis shows a highly significant improved overall survival for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTCGCCG, Nocova, NCIC CTG and Scottish intergroup trial. Proc Am Soc Clin Oncol 17: 361a, 1998 (Abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"260710_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1\u20136, 1996","journal-title":"N Engl J Med"},{"key":"260710_CR10","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1212\/WNL.39.3.368","volume":"39","author":"RB Lipton","year":"1989","unstructured":"Lipton RB, Apfel SC, Dutcher JP, Rosenberg R, Kaplan J, Berger A, Einzig AI, Wiernik P, Schaumberg HH: Taxol produces a predominantly sensory neuropathy. Neurology 39: 368\u2013373, 1989","journal-title":"Neurology"},{"key":"260710_CR11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0305-7372(89)90041-8","volume":"16","author":"RJ Cersosimo","year":"1989","unstructured":"Cersosimo RJ: Cisplatin neurotoxicity. Cancer Treat Rev 16: 195\u2013211, 1989","journal-title":"Cancer Treat Rev"},{"key":"260710_CR12","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1200\/JCO.1993.11.10.2010","volume":"11","author":"EK Rowinsky","year":"1993","unstructured":"Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 11: 2010\u20132020, 1993","journal-title":"J Clin Oncol"},{"key":"260710_CR13","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1006\/gyno.1996.0210","volume":"62","author":"E Connelly","year":"1996","unstructured":"Connelly E, Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J: Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol 62: 166\u2013168, 1996","journal-title":"Gynecol Oncol"},{"key":"260710_CR14","first-page":"352a","volume":"16","author":"MJ Piccart","year":"1997","unstructured":"Piccart MJ, Bertelsen K, Stuart G, James K, Cassidy J, Kaye S, Hoctin Boes G, Timmers P, Roy JA, Pecorelli S: Is cisplatin-paclitaxel (P-T) the standard in first-line treatment of advanced ovarian cancer (Ov Ca)? The EORTC-GCCG, NOCOVA, NCI-C and Scottish intergroup experience. Proc Am Soc Clin Oncol 16: 352a, 1997 (Abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"260710_CR15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/oxfordjournals.annonc.a059220","volume":"6","author":"TJ Postma","year":"1995","unstructured":"Postma TJ, Vermorken JB, Liefting AJM, Pinedo HM, Heimans JJ: Paclitaxel-induced neuropathy. Ann Oncol 6: 489\u2013494, 1995","journal-title":"Ann Oncol"},{"key":"260710_CR16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00003495-199753030-00008","volume":"53","author":"AJ Coukell","year":"1997","unstructured":"Coukell AJ, Faulds D: Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer. Drugs 53: 453\u2013482, 1997","journal-title":"Drugs"},{"key":"260710_CR17","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/1097-0142(19880601)61:11<2192::AID-CNCR2820611110>3.0.CO;2-A","volume":"61","author":"JE Mollman","year":"1988","unstructured":"Mollman JE, Glover DJ, Hogan WM, Furman RE: Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 61: 2192\u20132195, 1988","journal-title":"Cancer"},{"key":"260710_CR18","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.1996.14.7.2101","volume":"14","author":"G Kemp","year":"1996","unstructured":"Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14: 2101\u20132112, 1996","journal-title":"J Clin Oncol"},{"key":"260710_CR19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.410350310","volume":"35","author":"V Chaudhry","year":"1994","unstructured":"Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Comblath DR: Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35: 304\u2013311, 1994","journal-title":"Ann Neurol"},{"key":"260710_CR20","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.1996.14.7.1993","volume":"14","author":"C Wasserheit","year":"1996","unstructured":"Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H, Chachoua A, Wernz J, Zeleniuch-Jacquotte A, Blum R, Speyer J: Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol 14: 1993\u20131999, 1996","journal-title":"J Clin Oncol"},{"key":"260710_CR21","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.1991.9.9.1692","volume":"9","author":"EK Rowinsky","year":"1991","unstructured":"Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, Cornblath DR, Hendricks CB, Donehower RC: Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9: 1692\u20131703, 1991","journal-title":"J Clin Oncol"},{"key":"260710_CR22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1200\/JCO.1997.15.1.199","volume":"15","author":"G Cavaletti","year":"1997","unstructured":"Cavaletti G, Bogliun G, Crespi V, Marzorati L, Zincone A, Marzola M, Rota S, Galli A, Tredici P, Tredici G: Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer. J Clin Oncol 15: 199\u2013206, 1997","journal-title":"J Clin Oncol"},{"key":"260710_CR23","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0959-8049(97)00103-2","volume":"33","author":"T Berger","year":"1997","unstructured":"Berger T, Malayeri R, Doppelbauer A, Krajnik G, Huber H, Auff E, Pirker R: Neurological monitoring of neurotoxicity induced by paclitaxel\/cisplatin chemotherapy. Eur J Cancer 33: 1393\u20131399, 1997","journal-title":"Eur J Cancer"},{"key":"260710_CR24","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/oxfordjournals.annonc.a059324","volume":"6","author":"R Pirker","year":"1995","unstructured":"Pirker R, Krajnik G, Z\u00a8ochbauer S, Malayeri R, Kneussl M, Huber H: Paclitaxel\/cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann Oncol 6: 833\u2013835, 1995","journal-title":"Ann Oncol"},{"key":"260710_CR25","first-page":"352a","volume":"16","author":"JP Neijt","year":"1997","unstructured":"Neijt JP, Hansen M, Hansen SW, S\u00f8rensen PG, Sessa C, Witteveen PO, Engelholm SA, Stigaard L, Roer O, Lund B: Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin. Proc Am Soc Clin Oncol 16: 352a, 1997 (Abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"260710_CR26","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1023\/A:1008221310453","volume":"8","author":"A Lissoni","year":"1997","unstructured":"Lissoni A, Gabriele A, Gorga G, Tumolo S, Landoni F, Mangioni C, Sessa C: Cisplatin-, epirubicin-, and paclitaxelcontaining chemotherapy in uterine adenocarcinoma. Ann Oncol 8: 969\u2013972, 1997","journal-title":"Ann Oncol"},{"key":"260710_CR27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1023\/A:1008344507482","volume":"9","author":"TJ Postma","year":"1998","unstructured":"Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK: Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9: 739\u2013744, 1998","journal-title":"Ann Oncol"},{"key":"260710_CR28","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/1097-0142(19900915)66:6<1117::AID-CNCR2820660607>3.0.CO;2-O","volume":"66","author":"T Siegal","year":"1990","unstructured":"Siegal T, Haim N: Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 66: 1117\u20131123, 1990","journal-title":"Cancer"},{"key":"260710_CR29","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","volume":"332","author":"EK Rowinsky","year":"1995","unstructured":"Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med 332: 1004\u20131014, 1995","journal-title":"N Engl J Med"},{"key":"260710_CR30","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0959-8049(94)90459-6","volume":"30A","author":"JMA Van Gerven","year":"1994","unstructured":"Van Gerven JMA, Moll JWB, van den Bent MJ, Bontenbal M, van der Burg MEL, Verweij J, Vecht ChJ: Paclitaxel (Taxol) induces cumulative mild neurotoxicity. Eur J Cancer 30A: 1074\u20131077, 1994","journal-title":"Eur J Cancer"},{"key":"260710_CR31","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1200\/JCO.1992.10.5.795","volume":"10","author":"RW Gregg","year":"1992","unstructured":"Gregg RW, Molepo JM, Monpetit VJA, Mikael NZ, Redmond D, Gadia M, Stewart DJ: Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10: 795\u2013803, 1992","journal-title":"J Clin Oncol"},{"key":"260710_CR32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/BF01611731","volume":"15","author":"M R\u00a8oytt\u00a8a","year":"1986","unstructured":"R\u00a8oytt\u00a8a M, Raine CS: Taxol-induced neuropathy: chronic effects of local injection. J Neurocytol 15: 483\u2013496, 1986","journal-title":"J Neurocytol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006343818656.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1006343818656\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006343818656.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T09:00:02Z","timestamp":1749632402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1006343818656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,12]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,12]]}},"alternative-id":["260710"],"URL":"https:\/\/doi.org\/10.1023\/a:1006343818656","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,12]]}}}